Review Papers Against Their Own Results

 Quick Explanation Copied

 Long Explanation

Core evidence chain. In a registered, single-center cohort (UMIN000015703), 30 CAD patients had significantly lower B. vulgatus and B. dorei abundance than 30 matched controls (confirmed by qPCR), plus significantly higher fecal LPS; Bacteroides abundance correlated negatively with fecal LPS (r=−0.227, P=0.0838 for genus; significant for the two species) Yoshida et al. Circulation translational study.

Note: exact LPS values are in the original Figure 4C (median±IQR); the bar above schematizes the reported direction of effect, not precise magnitudes.

Causal mouse arm. ApoE−/− mice gavaged with live B. vulgatus+B. dorei (2.5×10⁹ cfu, 5×/week, 10 weeks) showed reduced aortic-root and en face lesion area, less macrophage/CD4⁺ T-cell infiltration, lower plasma LPS and cytokines (IL-2, IL-4, IL-6, IL-17A, IFN-γ, TNF-α), downregulated LpxA/LpxD, higher ZO-1, and more Tregs — with heat-killed bacteria ineffective, supporting live-microbe causality Mouse gavage causal experiment.

Critical caveats (authors partly acknowledged). 16S rRNA sequencing cannot resolve B. vulgatus vs B. dorei Species-differentiation study; statin use differed drastically (90% CAD vs 40% controls) and 100% of CAD patients were on antiplatelet agents — a major confounder the paper does not fully address Baseline medication imbalance; LAL assay measures total endotoxin, not immunogenicity; controls lacked angiography. Later work shows B. dorei effects are highly strain- and context-specific (e.g., pro-inflammatory metabolites induced by tetracyclines Doreamide pro-inflammatory induction study), cautioning against naive probiotic generalization. Interestingly, B. dorei also protects against influenza via bile-acid/TGR5 signaling B. dorei influenza protection study. What would falsify: multi-center metagenomics showing no species depletion, or human RCTs showing no lesion/endpoint benefit.

Author reviews:

 BGPT Paper Review

Study Novelty

First identification of specific CAD-depleted Bacteroides species with a live-vs-heat-killed causal mouse test mechanistically tied to gut LPS production and barrier function — a novel species-level translational link in 2018.

Scientific Quality

Registered trial, power calculation, deposited data, strong causal mouse design; but medication confounders (statins 90% vs 40%), no angiographic confirmation in controls, 16S species-resolution limits, and LAL assay lacking immunogenicity readout temper confidence.

Study Generality

Mechanistic LPS-TLR4-barrier axis generalizes to metabolic endotoxemia diseases, but findings are population- (Japanese, single-center) and strain-specific.

Study Usefulness

Defines a testable therapeutic target (live Bacteroides gavage) and a candidate dysbiosis marker (fecal LPS), directly informing probiotic/next-gen biotic development for CVD.

Study Reproducibility

Sequencing data deposited (PRJDB6472), detailed protocols and registered trial; but key dose-response, exact LPS values, and raw mouse flow data partly in supplement.

Explanatory Depth

Multi-level mechanism (fecal LPS → plasma LPS → dendritic-cell tolerogenicity → Tregs → reduced plaque) with heat-killed control; gaps remain in ZO-1 regulation and causality direction.